"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.
| Descriptor ID |
D014408
|
| MeSH Number(s) |
D23.101.140
|
| Concept/Terms |
Biomarkers, Tumor- Biomarkers, Tumor
- Tumor Biomarkers
- Markers, Biological Tumor
- Tumor Markers, Biological
- Markers, Tumor Metabolite
- Tumor Metabolite Markers
- Metabolite Markers, Tumor
- Marker, Tumor Metabolite
- Metabolite Marker, Tumor
- Tumor Metabolite Marker
- Tumor Markers, Biologic
- Biologic Tumor Markers
- Markers, Biologic Tumor
- Marker, Biologic Tumor
- Biologic Tumor Marker
- Tumor Marker, Biologic
- Biochemical Tumor Markers
- Markers, Biochemical Tumor
- Marker, Biochemical Tumor
- Biochemical Tumor Marker
- Tumor Marker, Biochemical
- Tumor Markers, Biochemical
- Carcinogen Markers
- Markers, Carcinogen
- Markers, Neoplasm Metabolite
- Neoplasm Metabolite Markers
- Marker, Neoplasm Metabolite
- Metabolite Marker, Neoplasm
- Neoplasm Metabolite Marker
- Metabolite Markers, Neoplasm
- Biological Tumor Markers
- Biological Tumor Marker
- Tumor Marker, Biological
- Marker, Biological Tumor
Markers, Tumor- Markers, Tumor
- Tumor Markers
- Biomarkers, Cancer
- Cancer Biomarkers
|
Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".
This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 2 | 3 |
| 1997 | 3 | 1 | 4 |
| 1998 | 6 | 4 | 10 |
| 1999 | 8 | 2 | 10 |
| 2000 | 5 | 1 | 6 |
| 2001 | 9 | 2 | 11 |
| 2002 | 6 | 9 | 15 |
| 2003 | 13 | 16 | 29 |
| 2004 | 12 | 6 | 18 |
| 2005 | 22 | 14 | 36 |
| 2006 | 18 | 11 | 29 |
| 2007 | 17 | 13 | 30 |
| 2008 | 19 | 15 | 34 |
| 2009 | 22 | 20 | 42 |
| 2010 | 18 | 22 | 40 |
| 2011 | 16 | 26 | 42 |
| 2012 | 21 | 16 | 37 |
| 2013 | 28 | 21 | 49 |
| 2014 | 28 | 19 | 47 |
| 2015 | 40 | 20 | 60 |
| 2016 | 32 | 28 | 60 |
| 2017 | 34 | 19 | 53 |
| 2018 | 36 | 21 | 57 |
| 2019 | 36 | 29 | 65 |
| 2020 | 37 | 25 | 62 |
| 2021 | 33 | 27 | 60 |
| 2022 | 0 | 31 | 31 |
| 2023 | 1 | 11 | 12 |
| 2024 | 10 | 28 | 38 |
| 2025 | 11 | 12 | 23 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
-
ESR1 Y537S and D538G Mutations Drive Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res. 2025 May 01; 31(9):1667-1675.
-
Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer. Clin Cancer Res. 2025 May 01; 31(9):1615-1624.
-
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response. JCO Precis Oncol. 2025 Apr; 9:e2400546.
-
Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. Cancer Discov. 2025 Apr 02; 15(4):818-837.
-
Uncommon Tumors of the Lung: Recently Described and Rediscovered Tumors. Arch Pathol Lab Med. 2025 Apr 01; 149(4):e87-e92.
-
Circulating tumor HPV DNA, antibodies to HPV16 early proteins, and oral HPV16 DNA as biomarkers for HPV-related oropharyngeal cancer screening. Cancer Biomark. 2025 Jan; 42(1):18758592241313323.
-
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation. Clin Cancer Res. 2025 Mar 17; 31(6):1057-1068.
-
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clin Cancer Res. 2025 Mar 17; 31(6):1069-1081.
-
High tumor CD161 expression predicts a survival advantage and marks a Th1-skewed microenvironment. Front Immunol. 2025; 16:1522755.